ABCL Q3 2022 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$101M+1740.6% YoY

Gross Profit

$86M85.2% margin

Operating Income

$38M37.2% margin

Net Income

$27M26.3% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+120.8%

Cash Flow

Operating Cash Flow

-$127M

Free Cash Flow

-$139M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$302M

Stockholders' Equity

$1.3B

Cash & Equivalents

$372M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$6M	+1740.6%
Gross Profit	$86M	$6M	+1467.7%
Operating Income	$38M	-$28M	+234.3%
Net Income	$27M	-$21M	+224.5%

Revenue Segments

Royalty

$93M92%

Research Fees

$8M7%

Milestone Payments

$400,0000%

License

$154,0000%